KSC · 207940.KS
Samsung Biologics Co.,Ltd.
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
Loading market information…
KOE · 246710.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
T&R Biofab Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow T&R Biofab Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
T&R Biofab Co., Ltd. is dedicated to advancing medical technology through the development of innovative devices designed for tissue regeneration and transplantation procedures. Their work primarily serves the fields of orthopedics, plastic surgery, and dentistry. The company's product line encompasses custom patient implants, such as craniomaxillofacial and dental meshes. They also provide cutting-edge bioinks for 3D bioprinting and cell culture, alongside solutions for stem cell research and delivery, and specialized coatings for laboratory scaffolds and culture dishes. This enterprise was established in 2013 and operates from its base in Siheung-si, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩1,487,000+₩121,000 (+8.86%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.16% below the high.
₩191,600+₩2,300 (+1.22%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
₩211,500-₩8,500 (-3.86%)
Alteogen Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.68% below the high.
₩309,500+₩2,500 (+0.81%)
Samsung Epis Holdings’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
₩77,700-₩100 (-0.13%)
SK Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.08% below the high.
₩40,000+₩300 (+0.76%)
HLB Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.2% below the high.
₩415,000+₩26,500 (+6.82%)
Hanmi Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.86% below the high.
₩75,100+₩400 (+0.54%)
Yuhan Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.87% below the high.
